TD Waterhouse Canada Inc. Buys 14,077 Shares of Becton, Dickinson and Company $BDX

TD Waterhouse Canada Inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 17.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 96,211 shares of the medical instruments supplier’s stock after purchasing an additional 14,077 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Becton, Dickinson and Company were worth $14,715,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC lifted its stake in shares of Becton, Dickinson and Company by 4.5% in the second quarter. Concurrent Investment Advisors LLC now owns 16,030 shares of the medical instruments supplier’s stock worth $2,426,000 after buying an additional 689 shares during the last quarter. NEOS Investment Management LLC grew its stake in Becton, Dickinson and Company by 1.9% in the 2nd quarter. NEOS Investment Management LLC now owns 46,442 shares of the medical instruments supplier’s stock valued at $7,028,000 after buying an additional 846 shares during the last quarter. Allen Mooney & Barnes Investment Advisors LLC bought a new position in Becton, Dickinson and Company in the 2nd quarter worth $16,078,000. Strengthening Families & Communities LLC raised its holdings in Becton, Dickinson and Company by 6.9% in the 2nd quarter. Strengthening Families & Communities LLC now owns 15,398 shares of the medical instruments supplier’s stock worth $2,330,000 after acquiring an additional 997 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Becton, Dickinson and Company during the 2nd quarter worth $285,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.5%

BDX opened at $184.78 on Friday. The company has a market capitalization of $50.91 billion, a P/E ratio of 55.66, a P/E/G ratio of 13.22 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm’s fifty day moving average price is $170.05 and its two-hundred day moving average price is $160.69. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Buying and Selling

In related news, EVP Michael Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BDX shares. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.